River Street Advisors LLC Purchases New Position in Zoetis Inc. $ZTS

River Street Advisors LLC purchased a new position in shares of Zoetis Inc. (NYSE:ZTS) during the first quarter, Holdings Channel reports. The firm purchased 11,701 shares of the company’s stock, valued at approximately $1,383,000.

A number of other institutional investors and hedge funds have also made changes to their positions in ZTS. OLD Second National Bank of Aurora raised its holdings in shares of Zoetis by 5.4% during the first quarter. OLD Second National Bank of Aurora now owns 29,206 shares of the company’s stock valued at $3,452,000 after acquiring an additional 1,486 shares during the last quarter. VCI Wealth Management LLC boosted its stake in Zoetis by 4.5% during the 1st quarter. VCI Wealth Management LLC now owns 11,027 shares of the company’s stock worth $1,304,000 after purchasing an additional 473 shares during the last quarter. GHP Investment Advisors Inc. grew its holdings in shares of Zoetis by 64.4% during the first quarter. GHP Investment Advisors Inc. now owns 6,239 shares of the company’s stock worth $738,000 after buying an additional 2,445 shares in the last quarter. Grey Ledge Advisors LLC raised its position in shares of Zoetis by 5.1% in the first quarter. Grey Ledge Advisors LLC now owns 10,741 shares of the company’s stock valued at $1,270,000 after buying an additional 518 shares during the last quarter. Finally, Louisiana State Employees Retirement System acquired a new stake in shares of Zoetis in the first quarter valued at about $2,542,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Price Performance

Shares of NYSE ZTS opened at $76.05 on Friday. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. The company has a market cap of $31.88 billion, a price-to-earnings ratio of 12.61, a price-to-earnings-growth ratio of 1.21 and a beta of 0.75. The stock’s 50-day moving average is $88.70 and its two-hundred day moving average is $110.94. Zoetis Inc. has a 1-year low of $72.38 and a 1-year high of $161.77.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. During the same quarter in the previous year, the firm posted $1.48 EPS. The business’s revenue for the quarter was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Analysts forecast that Zoetis Inc. will post 6.88 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be issued a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s payout ratio is presently 35.16%.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ZTS. Morgan Stanley restated an “overweight” rating and set a $115.00 price target on shares of Zoetis in a research report on Friday, May 15th. Argus reissued a “hold” rating on shares of Zoetis in a research report on Wednesday, May 27th. Stifel Nicolaus cut their price objective on shares of Zoetis from $95.00 to $85.00 and set a “hold” rating for the company in a research report on Friday. JPMorgan Chase & Co. decreased their target price on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Finally, Leerink Partners reissued a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. Six research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $133.08.

Key Zoetis News

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: Multiple firms, including Rosen Law Firm, Glancy Prongay Wolke & Rotter, Bronstein Gewirtz & Grossman, and others, announced or promoted class-action claims against Zoetis, increasing legal overhang and sentiment pressure on the stock.
• Neutral Sentiment: Zoetis also said it will host a webcast and conference call on August 6, 2026 to discuss second-quarter results, which may provide a more fundamental update for investors. Article Title

Insider Activity

In related news, Director Frank A. Damelio bought 6,650 shares of the stock in a transaction on Wednesday, May 13th. The shares were bought at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the purchase, the director owned 21,458 shares of the company’s stock, valued at $1,617,718.62. This trade represents a 44.91% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Paul Bisaro acquired 2,000 shares of the stock in a transaction that occurred on Wednesday, May 13th. The stock was purchased at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the transaction, the director owned 27,862 shares in the company, valued at $2,114,168.56. The trade was a 7.73% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 11,650 shares of company stock valued at $886,384 in the last ninety days. 0.22% of the stock is currently owned by company insiders.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.